We have observed that tumors from mice treated with 19L04c as a monotherapy or in combination with Pembrolizumab had a higher number of CD45+ leukocytes per gram of tissue (Figure 3C) translating into a higher absolute amount of CD45+ cells (Figure 3D) per tumor even though the tumors were smaller (Figure 3B), indicative of immune-mediated tumor destruction. The gene discussed is PTPRC; the disease is neoplasm.